Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Heinz-Gert Hoeffkes"'
Autor:
M. Schulze, Dirk Waldschmidt, Hans Werner Tessen, Volker Heinemann, C. Benedikt Westphalen, Matthias Groschek, Andreas Beringer, Norbert Marschner, Heinz-Gert Hoeffkes
Publikováno v:
Zeitschrift für Gastroenterologie. 58:332-340
ZusammenfasungVon allen Krebserkrankungen hat das metastasierte Pankreaskarzinom die schlechteste Prognose. Mit nab-Paclitaxel/Gemcitabin, FOLFIRINOX und Gemcitabin/Erlotinib gibt es mehrere Therapieoptionen, die das Gesamtüberleben der Patienten ve
Autor:
Alexander Reichart, Nils Homann, Thomas J. Ettrich, Salah-Eddin Al-Batran, Volker Kunzmann, Gabriele Margareta Siegler, Jörg Trojan, Daniel Pink, Claudia Pauligk, Arndt Vogel, Rudolf Schlag, Wolfgang Blau, Marina Schaaf, Thorsten Oliver Goetze, Oliver Waidmann, Caroline Schoenherr, Heinz-Gert Hoeffkes, Gerrit zur Hausen, Helmut Messmann, Ralf Hofheinz
Publikováno v:
Web of Science
Publons
Publons
4625 Background: Gemcitabine and nab-paclitaxel (NPG) is standard first-line therapy for metastatic pancreatic cancer (mPC), but the pivotal study did not include quality of life (QoL) analyses. Methods: The QOLIXANE-PARAGON study started as a prospe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f4c1107bb17f26d7044164ac4bcaf1ca
https://opus.bibliothek.uni-augsburg.de/opus4/frontdoor/index/index/docId/89663
https://opus.bibliothek.uni-augsburg.de/opus4/frontdoor/index/index/docId/89663
Autor:
Andreas Klameth, Philippe Kostrewa, Christian Wilhelm, Elisabeth Mack, Ralph Naumann, Ellen Wollmer, Mathias J. Rummel, S K Metzelder, Alexander Burchardt, Christoph Mann, Marius Dohse, Kristina Sohlbach, Heinz-Gert Hoeffkes, Corinna Trenker, Andreas Neubauer, Cornelia Brendel, Deborah Christen, Thomas Wündisch, Andreas Burchert
Publikováno v:
Leukemia & Lymphoma. 60:2056-2061
Patients who develop severe graft-versus-host disease (GvHD) after allogeneic stem cell transplantation (alloSCT) have a higher risk for invasive fungal infection (IFI). At our center, fluconazole prophylaxis is standard and upfront mold-effective pr
Autor:
Heinz Dürk, Arnold Ganser, Jan Rekowski, Andreas Hertel, Bernd Hertenstein, Lars Kurch, Matthias Sandmann, Winfried Brenner, Christiane Kreisel-Büstgens, Christiane Franzius, Wolfram Klapper, Matthias Weckesser, Aristoteles Giagounidis, Martin Freesmeyer, Thomas Krohn, Volker Runde, Dirk Behringer, Michael Heike, Stefan P. Müller, Frank Kroschinsky, Regina Moeller, Rolf Larisch, Hubertus Hautzel, Christine Schmitz, Gerhard Heil, Rolf M. Mesters, Ulrich Dührsen, Karl-Heinz Jöckel, Ferras Alashkar, Helga Bernhard, Dietmar Wacker, Uwe M. Martens, Stefan Mahlmann, Stefan Wilop, Jörg Kotzerke, Ronald Boellaard, Paul La Rosée, Gabriele Prange-Krex, Andreas Hüttmann, Heinz Gert Hoeffkes, Uwe Haberkorn, Guido Trenn, Dieter Hoelzer, Marcus Brinkmann, Frank M. Bengel
Publikováno v:
Schmitz, C, Rekowski, J, Müller, S P, Hertenstein, B, Franzius, C, Ganser, A, Bengel, F M, Kroschinsky, F, Kotzerke, J, La Rosée, P, Freesmeyer, M, Hoeffkes, H G, Hertel, A, Behringer, D, Mesters, R, Weckesser, M, Mahlmann, S, Haberkorn, U, Martens, U, Prange-Krex, G, Brenner, W, Giagounidis, A, Moeller, R, Runde, V, Sandmann, M, Hautzel, H, Wilop, S, Krohn, T, Dürk, H, Heike, M, Alashkar, F, Brinkmann, M, Trenn, G, Wacker, D, Kreisel-Büstgens, C, Bernhard, H, Heil, G, Larisch, R, Kurch, L, Jöckel, K H, Hoelzer, D, Klapper, W, Boellaard, R, Dührsen, U & Hüttmann, A 2020, ' Baseline and interim PET-based outcome prediction in peripheral T-cell lymphoma : A subgroup analysis of the PETAL trial ', Hematological Oncology, vol. 38, no. 3, pp. 244-256 . https://doi.org/10.1002/hon.2697
Hematological Oncology, 38(3), 244-256. John Wiley and Sons Ltd
Hematological Oncology, 38(3), 244-256. John Wiley and Sons Ltd
The prospective randomized Positron Emission Tomography (PET)-Guided Therapy of Aggressive Non-Hodgkin Lymphomas (PETAL) trial was designed to test the ability of interim PET (iPET) to direct therapy. As reported previously, outcome remained unaffect
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::099b8783f9b6d6dc0cff5a6c834fda48
https://research.vumc.nl/en/publications/15e83158-ea3b-4feb-ba8a-34400272cd82
https://research.vumc.nl/en/publications/15e83158-ea3b-4feb-ba8a-34400272cd82
Autor:
Andreas, Burchert, Gesine, Bug, Lea V, Fritz, Jürgen, Finke, Matthias, Stelljes, Christoph, Röllig, Ellen, Wollmer, Ralph, Wäsch, Martin, Bornhäuser, Tobias, Berg, Fabian, Lang, Gerhard, Ehninger, Hubert, Serve, Robert, Zeiser, Eva-Maria, Wagner, Nicolaus, Kröger, Christine, Wolschke, Michael, Schleuning, Katharina S, Götze, Christoph, Schmid, Martina, Crysandt, Eva, Eßeling, Dominik, Wolf, Ying, Wang, Alexandra, Böhm, Christian, Thiede, Torsten, Haferlach, Christian, Michel, Wolfgang, Bethge, Thomas, Wündisch, Christian, Brandts, Susanne, Harnisch, Michael, Wittenberg, Heinz-Gert, Hoeffkes, Susanne, Rospleszcz, Alexander, Burchardt, Andreas, Neubauer, Markus, Brugger, Konstantin, Strauch, Carmen, Schade-Brittinger, Stephan K, Metzelder
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 38(26)
Despite undergoing allogeneic hematopoietic stem cell transplantation (HCT), patients with acute myeloid leukemia (AML) with internal tandem duplication mutation in theIn a randomized, placebo-controlled, double-blind phase II trial (SORMAIN; German
Autor:
C Benedikt, Westphalen, Volker, Heinemann, Hans Werner, Tessen, Matthias, Groschek, Heinz-Gert, Hoeffkes, Norbert, Marschner, Mathias, Schulze, Andreas, Beringer, Dirk, Waldschmidt
Publikováno v:
Zeitschrift fur Gastroenterologie. 58(4)
Metastatic pancreatic cancer has the worst prognosis of all cancers. With nab-Paclitaxel/gemcitabine, FOLFIRINOX, and gemcitabine/erlotinib, several treatment options are available which improve the patient's overall survival. Especially for patients
Autor:
Martin Bornhäuser, Andreas Burchert, Susanne Harnisch, Michael Schleuning, Konstantin Strauch, Katharina Götze, Christian Michel, Christian Brandts, Ellen Wollmer, Susanne Rospleszcz, Thomas Wündisch, Alexandra Böhm, Fabian Lang, Alexander Burchardt, Jürgen Finke, Eva-Maria Wagner, Eva Eßeling, Nicolaus Kröger, Torsten Haferlach, Tobias Berg, Andreas Neubauer, Carmen Schade-Brittinger, Markus Brugger, Ying Wang, Dominik Wolf, S K Metzelder, Matthias Stelljes, Ralph Wäsch, Christine Wolschke, Gerhard Ehninger, Gesine Bug, Robert Zeiser, Hubert Serve, Martina Crysandt, Christian Thiede, Michael Wittenberg, Christoph Röllig, Christoph Schmid, Lea V. Fritz, Wolfgang Bethge, Heinz-Gert Hoeffkes
Publikováno v:
J. Clin. Oncol. 38, 2993-3002 (2020)
PURPOSE Despite undergoing allogeneic hematopoietic stem cell transplantation (HCT), patients with acute myeloid leukemia (AML) with internal tandem duplication mutation in the FMS-like tyrosine kinase 3 gene ( FLT3-ITD) have a poor prognosis, freque
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::36839bb69f3099cd0f1dfab0c2baaf2a
https://push-zb.helmholtz-muenchen.de/frontdoor.php?source_opus=59685
https://push-zb.helmholtz-muenchen.de/frontdoor.php?source_opus=59685
Autor:
Reinhard Marks, Stephan Stilgenbauer, Bernd Metzner, Martin Maisenhölder, Christian Schmidt, Peter Borchmann, Bettina Altmann, Flyer Trial Investigators, Andreas Neubauer, Marita Ziepert, Andreas Viardot, Niels Murawski, Judith Dierlamm, Norbert Frickhofen, Francesco Merli, Michael Kneba, Harald Holte, Gerhard Held, Heinz-Gert Hoeffkes, Eva Lengfelder, Rolf Mahlberg, Norbert Schmitz, Andreas Rosenwald, Mathias Witzens-Harig, Frank Hartmann, Alessandra Tucci, Ulrich Keller, Markus Loeffler, Mathias Hänel, Martin Soekler, Ralf Ulrich Trappe, Lorenz Trümper, Lorenz Thurner, Michael Pfreundschuh, Alice Di Rocco, Massimo Federico, Viola Poeschel, Ofer Shpilberg, Josif Amam, Christian Berdel, Konstantinos Christofyllakis, Peter de Nully Brown
Publikováno v:
SSRN Electronic Journal.
Background: Six cycles of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone) or R-CHOP-like chemotherapy are the standard treatment for aggressive B-cell non-Hodgkin's lymphoma. We hypothesized that four cycles of CHOP pl
Autor:
Viola Poeschel, Martin Sökler, Andreas Neubauer, Andreas Viardot, Stephan Stilgenbauer, Ulrich Keller, Gerhard Held, Michael Pfreundschuh, Kerstin Habersang, Andreas Rank, Jonas Matthias Jabs, Bettina Altmann, Joerg Thomas Bittenbring, Heinz-Gert Hoeffkes, Marita Ziepert, Rolf Mahlberg
Publikováno v:
Blood. 136:11-11
Vitamin D deficient patients suffering from diffuse large B-cell lymphoma (DLBCL) treated with R-CHOP have lower overall survival. This especially applies for patients with vitamin D levels ≤8 ng/ml (Bittenbring et al. J Clin Oncol. 2014; 32:3242-8
Autor:
Bettina Altmann, Viola Poeschel, Harald Holte, Gerhard Held, Bernd Metzner, Niels Murawski, Ulrich Keller, Josif Amam, Norbert Schmitz, Peter Borchmann, Lorenz Truemper, Konstantinos Christofyllakis, Christian Berdel, Stephan Stilgenbauer, Lorenz Thurner, Reinhard Marks, Andreas Viardot, Michael Pfreundschuh, Heinz-Gert Hoeffkes, Christian Schmidt, Marita Ziepert, Rolf Mahlberg, Mathias Witzens-Harig, Lothar Kanz, Markus Loeffler
Publikováno v:
Blood. 132:781-781
Background: 6 cycles CHOP-like chemotherapy plus rituximab (6x R-CHOP) are the standard treatment for young patients with DLBCL. The MInT trial established a subgroup with favourable prognosis as defined as aaIPI=0 and no bulky disease [Pfreundschuh